Tag: PredicineCARE

Predicine announces six studies showcasing MRD and liquid

HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) — Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. The company will present six compelling poster studies, unveiling the future of liquid biopsy solutions. These poster presentations will…

Continue Reading Predicine announces six studies showcasing MRD and liquid

Liquid Biopsy Market Size to Surpass USD 34.71 Billion by 2030, exhibiting a CAGR of 23.3%

Fortune Business Insights As per the report by Fortune Business Insights, The Global Liquid Biopsy Market size is projected to reach USD 34.71 Billion by 2030, at a CAGR of 23.3% during the forecast period. Pune, India, Aug. 14, 2023 (GLOBE NEWSWIRE) — The global liquid biopsy market size was…

Continue Reading Liquid Biopsy Market Size to Surpass USD 34.71 Billion by 2030, exhibiting a CAGR of 23.3%

Predicine Receives CE-IVD Mark for Blood and Urine Liquid Biopsy Assay

NEW YORK – Molecular testing company Predicine said on Tuesday that its blood and urine cell-free DNA (cfDNA) assay, PredicineCare, has secured a CE-IVD mark. The targeted next-generation sequencing (NGS) assay is developed to detect single nucleotide variants (SNVs), insertions and deletions (indels), DNA rearrangements (fusions), and copy number variations…

Continue Reading Predicine Receives CE-IVD Mark for Blood and Urine Liquid Biopsy Assay

New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News

HAYWARD, Calif., Sept. 16, 2021 /PRNewswire-PRWeb/ — Predicine, Inc. announced today results from a liquid biopsy study demonstrating the clinical application of utilizing the PredicineCARE liquid biopsy NGS assay to serially monitor changes in ctDNA levels in patients with metastatic castration-resistant prostate cancer (mCRPC). The European Urology study evaluated the effects…

Continue Reading New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News